Chasing the Paradigm: Clinical Translation of 25 Years of Tissue Engineering
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
In the past 25 years, the tissue engineering field has made incredible strides in developing tangible therapies for patients in need. Applications of the tissue engineering paradigm, involving varying configurations of cells, materials, and biochemical factors, have been explored for their regenerative capacity of virtually all tissue types. The impact and learning opportunities of current tissue engineering that inspired clinical successes are summarized. In addition, challenges associated with the translation and scale-up of therapies and replacements for complex organs, such as the heart and liver, are addressed. Platforms of research thrusts, specifically cell source, materials, fabrication, scalability, and Food and Drug Administration regulatory changes, and their respective innovations are identified for their potential to address these problems. Ideally, through their progress, tissue engineering strategies can be used to create a diverse range of easily accessible patient-specific treatments that more effectively improve quality of life. Impact Statement: In this Perspective, we discuss the impact of the past 25 years of tissue engineering on the development of clinical therapies. Based on their success and other significant research accomplishments, platforms of innovation were identified. Their discoveries will enable tissue engineering inspired therapies to meet the requirements necessary for large-scale manufacturing and Food and Drug Administration (FDA) approval for a diverse range of indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3D bioprinting of tissues and organs
Murphy, S. V., & Atala, A. (2014) · Nature Biotechnology · doi:10.1038/nbt.2958 · Cited by 7,034
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 1×
“determine drug responses on patient-derived cells.(49,91,92) This technology is currently being evaluated by the FDA and is expected to have dramatic impacts on the medical field, leading to more efficacious use of drugs, lowering costs of approval studies, and predicting negative side effects.”
BackgroundSynthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels
Yue, K., Trujillo-de Santiago, G., Alvarez, M. M., Tamayol, A., Annabi, N., & Khademhosseini, A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.045 · Cited by 3,146
Self-citationAdvances in engineering hydrogels
Zhang, Y. S., & Khademhosseini, A. (2017) · Science · doi:10.1126/science.aaf3627 · Cited by 2,908
Self-citationPerfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart
Ott, H. C., Matthiesen, T. S., Goh, S.-K., Black, L. D., Kren, S. M., Netoff, T. I., & Taylor, D. A. (2008) · Nature Medicine · doi:10.1038/nm1684 · Cited by 2,650
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink
Pati, F., Jang, J., Ha, D.-H., Won Kim, S., Rhie, J.-W., Shim, J.-H., Kim, D.-H., & Cho, D.-W. (2014) · Nature Communications · doi:10.1038/ncomms4935 · Cited by 1,904 · cited 2×
“2E) or hydrogels into tissue-specific structures for in vitro modeling or facilitating proper in vivo tissue formation.(70,71) Through the development of bioinks, precise control over deposition location, different printing techniques, materials with specific functionalization and mechanical properties, and distinct c…”
BackgroundMethodThree-dimensional bioprinting of thick vascularized tissues
Kolesky, D. B., Homan, K. A., Skylar-Scott, M. A., & Lewis, J. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521342113 · Cited by 1,492 · cited 1×
“Current innovations of thick vascularized tissues with extended viability of multiple cell types demonstrate the potential development of complex, functional ex vivo organs that mimic native architecture.(80) Combined with personalized cell sources and applicable materials, engineered tissues could be developed that a…”
BackgroundOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185 · cited 2×
“This technology is currently being evaluated by the FDA and is expected to have dramatic impacts on the medical field, leading to more efficacious use of drugs, lowering costs of approval studies, and predicting negative side effects.(92,93) In addition, the reach expands beyond direct patient impact.”
BackgroundHydrogel bioprinted microchannel networks for vascularization of tissue engineering constructs
Bertassoni, L. E., Cecconi, M., Manoharan, V., Nikkhah, M., Hjortnaes, J., Cristino, A. L., Barabaschi, G., Demarchi, D., Dokmeci, M. R., Yang, Y., et al. (2014) · Lab Chip · doi:10.1039/c4lc00030g · Cited by 944
Self-citationXenogeneic extracellular matrix as a scaffold for tissue reconstruction
Badylak, S. F. (2004) · Transplant Immunology · doi:10.1016/j.trim.2003.12.016 · Cited by 747
Decellularization Strategies for Regenerative Medicine: From Processing Techniques to Applications
Gilpin, A., & Yang, Y. (2017) · BioMed Research International · doi:10.1155/2017/9831534 · Cited by 742
Vegas, A. J., Veiseh, O., Gürtler, M., Millman, J. R., Pagliuca, F. W., Bader, A. R., Doloff, J. C., Li, J., Chen, M., Olejnik, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4030 · Cited by 710 · cited 1×
“Examples include the application of polymer-encapsulated engineered insulin-producing cells, which recently demonstrated long-term glycemic control in a diabetic rat model.(89) Commercial efforts are working toward applying the encapsulated engineered cell platform in clinical trials for the treatment of diabetes, hem…”
BackgroundSelf-citationJang, J., Park, H.-J., Kim, S.-W., Kim, H., Park, J. Y., Na, S. J., Kim, H. J., Park, M. N., Choi, S. H., Park, S. H., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.026 · Cited by 673
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639 · cited 1×
“Other strategies include the use of viral vectors to remove the human leukocyte antigen expression of stem cells, creating an ‘‘off the shelf’’ donor cell that can be applied to any patient without an immune response.(57)”
3D biofabrication strategies for tissue engineering and regenerative medicine
Bajaj, P., Schweller, R. M., Khademhosseini, A., West, J. L., & Bashir, R. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105155 · Cited by 632
Self-citationCartilage repair: generations of autologous chondrocyte transplantation
Marlovits, S., Zeller, P., Singer, P., Resinger, C., & Vécsei, V. (2006) · European Journal of Radiology · doi:10.1016/j.ejrad.2005.08.009 · Cited by 388
In Vivo Cellular Reprogramming: The Next Generation
Srivastava, D., & DeWitt, N. (2016) · Cell · doi:10.1016/j.cell.2016.08.055 · Cited by 292
Parmaksiz, M., Dogan, A., Odabas, S., Elçin, A. E., & Elçin, Y. M. (2016) · Biomedical Materials · doi:10.1088/1748-6041/11/2/022003 · Cited by 268 · cited 2×
“Decellularized matrices of many tissue types have been clinically tested and are commercially available for many indications.(61,62) In addition, decellularized whole organs keep vascular networks intact and have the potential to be reseeded with autologous cells for tissue maturation before implantation (Fig.”
BackgroundZaulyanov, L., & Kirsner, R. S. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.93 · Cited by 266
Progress and challenges in large-scale expansion of human pluripotent stem cells
Kropp, C., Massai, D., & Zweigerdt, R. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2016.09.032 · Cited by 167
Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants
Edri, R., Gal, I., Noor, N., Harel, T., Fleischer, S., Adadi, N., Green, O., Shabat, D., Heller, L., Shapira, A., et al. (2019) · Advanced Materials · doi:10.1002/adma.201803895 · Cited by 128 · cited 1×
“Recent efforts investigating the generation of personalized hydrogels from patient biopsies seeded with autologous cells have potential applications for many organ types with reduced risk of immune rejection.(69)”
Background
Cited by
Synthetic alternatives to Matrigel
Aisenbrey, E. A., & Murphy, W. L. (2020) · Nature Reviews Materials · doi:10.1038/s41578-020-0199-8 · Cited by 1,016
Design, printing, and engineering of regenerative biomaterials for personalized bone healthcare
Jia, Z., Xu, X., Zhu, D., & Zheng, Y. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101072 · Cited by 176
Ultrasound-assisted tissue engineering
Melde, K., Athanassiadis, A. G., Missirlis, D., Shi, M., Seneca, S., & Fischer, P. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00166-5 · Cited by 59
“Thus, most studies on tissue engineering remain limited to a small subset of tissues, such as skin, bone and cartilage 2 .”
Metadata
- Authors
- Hoffman, T., Khademhosseini, A., & Langer, R.
- Venue
- Tissue Engineering Part A
- Publisher
- SAGE Publications
- Published
- 2019-05
- Volume
- 25
- Issue
- 9-10
- Pages
- 679-687
- ISSN
- 1937-3341 (ISSN-L)
- 1937-335X
- OpenAlex
- W2915026905
- Cited by
- 118
- References
- 22
- FWCI
- 15.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.